Last updated: 2026-09-16 12:10:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
ICU Medical Inc. (ICUI) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $157.00, with a market capitalisation of $3.94B and a P/E ratio of 129.55. Over the past 52 weeks, its price has ranged from $112.50 to $192.85. This page covers its latest market performance, valuation, price trends and company information.
$3.94B | |
$156.35 | |
$321.70 | |
$19.98 | |
$155.88 | |
288.00 | |
296.59K | |
129.55 | |
$192.85 | |
$112.50 | |
-- | |
-- |
ICU Medical Inc. (ICUI) is trading at $157.00 in pre-market trading as of 2026-09-16 12:06:00, up 0.72% ($1.12) from the previous close of $155.88
Pre-market trading shows how investors are pricing ICUI before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, ICU Medical Inc. (ICUI) moved from $167.58 to $157.00, representing a decline of 6.31% ($10.58).
The stock traded between $154.97 and $167.87 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 216.04 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 55.4%
ICUI is currently trading at $157.00, placing it 55.4% of the way from its 52-week low of $112.50 to its 52-week high of $192.85. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 13000 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of ICU Medical Inc. (ICUI) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.